Overview Request Sample Pages Request Customization Download PDF
You are viewing: Europe Biochips Market analysis
Part of: Biochips Market (Global)

The Europe Biochips Market was valued at $3546 Million in 2025 and projected to reach to $5450.9 Million by 2030, representing a compound annual growth rate of 9.0%. Europe's biochips market is poised for sustained expansion driven by the region's commitment to advanced healthcare technologies and personalized medicine initiatives.

Europe Biochips Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Europe Biochips Market Trends and Insights

  • This expansion reflects Europe's strong healthcare infrastructure, advanced research capabilities, and increasing adoption of personalized medicine across the region.
  • Europe is positioning itself as a leader in biochip innovation, driven by regulatory support and substantial investments in biotechnology. The European biochips market benefits from a mature healthcare ecosystem and stringent quality standards that foster innovation and consumer confidence.
  • Between 2025 and 2030, Europe is expected to capture significant market share through development of diagnostic and therapeutic biochips.
  • The region's emphasis on precision medicine and genomic research is accelerating biochip deployment across hospitals, research institutions, and diagnostic laboratories throughout Europe. Europe's competitive advantage stems from its collaborative research networks, favorable regulatory frameworks, and strong pharmaceutical and diagnostics sectors.
  • The market trajectory through 2030 underscores Europe's commitment to advancing point-of-care testing and personalized healthcare solutions, positioning the continent as a key growth engine in the global biochips landscape..

Key Market Statistics

  • CAGR (2025-2030) 9.0% CAGR
  • Market Size, 2025 ~USD 3546 Million
  • Forecast, 2030 ~USD 5450.9 Million
  • Geography Europe

Europe Biochips Market Overview

Market Valuation & Growth :

Europe's biochips market is valued at $3,546 million in 2025 and is projected to reach $5,450.9 million by 2030, demonstrating a robust 9.0% CAGR, outpacing the global average of 8.8%.

Healthcare Infrastructure Leadership :

Europe's advanced healthcare infrastructure and strong regulatory frameworks position the region as a leader in biochip adoption, with significant investments in research and development across major economies.

Personalized Medicine Adoption :

Increasing adoption of personalized medicine and precision diagnostics across European healthcare systems is driving demand for innovative biochip technologies and solutions.

Regional Market Concentration :

Germany, UK, and France collectively represent over 60% of Europe's biochips market, with these nations leading in innovation, clinical applications, and healthcare spending.

Europe Biochips Market Dynamics

  • The strong regulatory environment, coupled with substantial R&D investments from both public and private sectors, creates favorable conditions for biochip innovation and commercialization.
  • Major European healthcare systems are increasingly integrating biochip diagnostics into clinical workflows, supporting market growth. The forecast period through 2030 will see accelerated adoption across diagnostic, therapeutic, and monitoring applications.
  • European pharmaceutical and medical device companies are investing heavily in biochip development, while academic institutions continue to drive breakthrough research.
  • Government support for digital health and precision medicine initiatives further strengthens the market trajectory, positioning Europe as a key growth engine in the global biochips landscape..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • Europe's biochips market is projected to grow from $3,546 million in 2025 to $5,450.9 million by 2030 at a 9.0% CAGR.
      • Europe leads in biochip innovation due to advanced healthcare infrastructure, regulatory support, and strong R&D investments.
      • Precision medicine and genomic research initiatives are driving accelerated biochip adoption across European healthcare institutions.
      • Europe's collaborative research networks and favorable regulatory environment position the region as a competitive global biochips hub.

      Biochips Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment MICROFLUIDICS (Fabrication Technology)
      Forecast Period 2025–2030
      Growth Rate CAGR of 8.8% from 2025 to 2030
      Largest Segment MICROARRAYS (Fabrication Technology)
      Market Size Base Year (Billions) ~USD 14.01 (2025)
      Revenue Forecast (Billions) ~USD 21.36 (2030)
      Segments Covered Products & Services, Type, Application, Fabrication Technology, End User, Product & Service

      Europe Biochips Market Report Segmentation

      6 segment dimensions are covered across the global market.

      By Products & Services

      • Consumables
      • Instruments
      • Software & Services

      By Type

      • Cell Arrays
      • Dna Chips
      • Lab-On-A-Chip
      • Protein Chips
      • Tissue Arrays

      By Application

      • Agricultural Biotechnology
      • Cancer Diagnosis & Treatment
      • Clinical Diagnostic
      • Diagnostics
      • Drug Discovery
      • Expression Profiling
      • Gene Expression
      • Genomics
      • High-Throughput Screening
      • Ivd & Poc
      • Other Dna Chip Applications
      • Other Loac Applications
      • Other Protein Chip Applications
      • Proteomics
      • Snp Genotyping

      By Fabrication Technology

      • Microarrays
      • Microfluidics

      By End User

      • Academic & Research Institutes
      • Biotechnology & Pharmaceutical Companies
      • Contract Research Organizations
      • Hospitals & Diagnostic Centers
      • Other End Users

      By Product & Service

      • Consumables
      • Instruments
      • Software & Services

      REST OF EUROPE: BIOCHIPS MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      ACADEMIC & RESEARCH INSTITUTES64.569.875.581.788.495.8103.9112.88.4
      BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES335365.5399.1436476.3520.8570624.49.4
      CONTRACT RESEARCH ORGANIZATIONS39.643.64852.958.364.37178.410.3
      HOSPITALS & DIAGNOSTIC CENTERS136.5146.1156.5167.8179.8192.9207.2222.77.3
      OTHER END USERS36.639.542.645.949.553.557.862.58
      TOTAL612.3664.5721.7784.3852.4927.31009.91100.88.8

      EUROPE: BIOCHIPS MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      ACADEMIC & RESEARCH INSTITUTES320.1346.7375.6407.2441.4479520.4565.88.5
      BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES1656.11809.51978.22164.12367.32592.12841.43117.29.5
      CONTRACT RESEARCH ORGANIZATIONS196.6216.7238.9263.7291321.4355.4393.310.5
      HOSPITALS & DIAGNOSTIC CENTERS676.9725.8778.7836897.4964.31037.31116.87.5
      OTHER END USERS150161.8174.6188.6203.6220.1238.1257.88.1
      TOTAL2999.83260.435463859.54200.74576.94992.65450.99

      Target Audience

      • Medical Device Manufacturers : Develop market expansion strategies and product localization plans for European markets with detailed competitive analysis and regulatory pathway guidance specific to each country.
      • Healthcare Investors & PE Firms : Identify high-potential investment opportunities in European biochip companies and healthcare technology startups with market sizing and growth projections through 2030.
      • Pharmaceutical Companies : Assess biochip integration opportunities for drug development, companion diagnostics, and personalized medicine initiatives across European markets and healthcare systems.
      • Research Institutions & Academics : Benchmark European biochip research capabilities, identify collaboration opportunities, and understand commercialization pathways for academic innovations in the region.
      • Healthcare Providers & Hospital Networks : Evaluate biochip technology adoption for diagnostic and therapeutic applications with insights on clinical implementation, reimbursement models, and patient outcomes across Europe.

      Key Companies in the Europe Biochips Market

      CompanyHQOwnershipStrongest segments
      ATS AUTOMATION TOOLING SYSTEMS INCCanadaPublic CompanyCustom automated manufacturing and assembly systems,Pre- and post-automation services,Software and digital factory solutions,
      DECODE GENETICSIcelandPrivate CompanyInternal discovery and target validation for Amgen,External research collaborations and licensing,Population genomics and healthcare-linked projects,
      JABILUnited StatesPublic CompanyRegulated Industries (Healthcare, Automotive, Industrial, Packaging),Intelligent Infrastructure (5G, Cloud, Networking, Storage, Digital Building),Connected Living and Digital Commerce (Mobility, Connected Devices, Retail, Digital Commerce Ecosystem),
      AT&SCanadaPublic CompanyTurnkey automation systems (design, build, commissioning),Lifecycle services (pre- and post-automation, maintenance, retrofits),Contract manufacturing and integration,
      X-FABBelgiumPublic CompanyAutomotive analog & mixed-signal (incl. high-voltage, BCD, safety ICs),Power semiconductors (SiC, GaN, high-voltage discretes),MEMS & sensor platforms (pressure, inertial, image, gas/flow, photodiodes),
      GE HEALTHCAREUnited StatesPublic CompanyImaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS),
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response (TB and transplant) assays,Oncology, sexual and reproductive health assays,
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics systems, reagents, and quality controls,Life Science instruments and consumables for research and biopharma,Informatics and software solutions,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      STANDARD BIOTOOLSUnited StatesPublic CompanyProteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics platforms and consumables (Biomark X9 and qPCR systems),Services, software, and other,
      10X GENOMICSUnited StatesPublic CompanyChromium instruments,Chromium consumables & kits (incl. QuantumScale),Visium spatial platform (instruments, slides, reagents),
      CEPHEIDUnited StatesPrivate CompanyGeneXpert instruments,Xpert test cartridges (infectious disease & HAIs),Xpert test cartridges (virology, oncology, genetics),
      BIOMéRIEUXFrancePublic CompanyClinical microbiology (VITEK, BACT/ALERT, CHROMID, culture media, ETEST, API),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, EPISEQ),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA),
      REVVITYUnited StatesPublic CompanyDiagnostics & Immunodiagnostics (prenatal, newborn, infectious, autoimmune, specialty),Life Science Reagents & Assay Platforms,Genomic & NGS Workflow Solutions,
      DIASORIN S.P.A.ItalyPublic CompanyImmunodiagnostics (LIAISON XL / XS reagents and systems),Molecular diagnostics (Simplexa, LIAISON PLEX assays),xMAP technology and other specialty IVD solutions,

      ATS AUTOMATION TOOLING SYSTEMS INC

      ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 that employs 7,000 people. The company specializes in automation and tooling systems for industrial applications.

      DECODE GENETICS

      Decode Genetics is a private Icelandic company founded in 1996 with 331 employees. The company focuses on genetic research and analysis.

      JABIL

      Jabil is a large American public company founded in 1966 with 135,000 employees. The company provides electronics manufacturing services and solutions.

      AT&S

      AT&S is a Canadian public company founded in 1978 with 7,000 employees. The company specializes in automation and tooling systems.

      X-FAB

      X-FAB is a Belgian public semiconductor company founded in 1992 with 4,300 employees. The company manufactures specialty semiconductor products.

      GE HEALTHCARE

      GE Healthcare is an American public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a large American public company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, and services for research and diagnostics.

      ILLUMINA, INC.

      Illumina, Inc. is an American public company founded in 1998 with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is an American public company founded in 1999 with 18,000 employees. The company provides analytical instruments and software for life sciences and diagnostics.

      QIAGEN

      Qiagen is a Dutch public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation products.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is an American public company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research and clinical diagnostics products.

      ABBOTT

      Abbott is a large American public company founded in 1888 with 115,000 employees. The company develops and manufactures pharmaceuticals, diagnostics, and medical devices.

      STANDARD BIOTOOLS

      Standard Biotools is an American public company founded in 1999 with 387 employees. The company develops microfluidic and single-cell analysis solutions.

      10X GENOMICS

      10X Genomics is an American public company founded in 2012 with 1,178 employees. The company develops single-cell and spatial genomics solutions.

      CEPHEID

      Cepheid is an American private company founded in 1996 with 1,700 employees. The company manufactures molecular diagnostics and point-of-care testing systems.

      BIOMéRIEUX

      bioMérieux is a French public company founded in 1963 with 14,894 employees. The company develops and manufactures in vitro diagnostics and microbiology testing systems.

      REVVITY

      Revvity is an American public company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.

      DIASORIN S.P.A.

      DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees. The company develops and manufactures in vitro diagnostic products.

      Europe vs. other regions

      HowEurope compares to the other 3 regional blocs covered in this market.

      North America
      ~USD 9656.4 Million · 8.4% wtd CAGR ·
      Asia Pacific
      ~USD 5247.1 Million · 9.5% wtd CAGR ·
      Latin America
      ~USD 795.5 Million · 8% wtd CAGR ·
      Middle East & Africa
      ~USD 206.4 Million · 6.4% wtd CAGR ·

      Countries within Europe - compare and drill down

      Country2025 size (native)
      GermanyUSD 1308.6 Million
      UKUSD 1055.9 Million
      FranceUSD 813.6 Million
      ItalyUSD 529.7 Million
      SpainUSD 343.1 Million
      NetherlandsUSD 299.3 Million
      Rest Of EuropeUSD 1100.8 Million

      Country market size visualization

      Germany
      USD 1308.6 Million
      UK
      USD 1055.9 Million
      France
      USD 813.6 Million
      Italy
      USD 529.7 Million
      Spain
      USD 343.1 Million
      Netherlands
      USD 299.3 Million
      Rest Of Europe
      USD 1100.8 Million

      Reasons to Buy this Report

      • Regional Market Segmentation : Gain detailed insights into Europe's biochips market with country-level breakdowns for Germany, UK, France, Italy, Spain, Netherlands, and Rest of Europe, enabling targeted market entry strategies.
      • Growth Trajectory Analysis : Understand the 9.0% CAGR growth dynamics specific to Europe, outperforming global averages, with comprehensive forecasts through 2030 for strategic planning and investment decisions.
      • Competitive Landscape Intelligence : Identify leading European biochip manufacturers, research institutions, and healthcare providers driving innovation and market adoption across the region's diverse healthcare ecosystems.
      • Regulatory & Healthcare Insights : Navigate Europe's complex regulatory environment with analysis of CE marking requirements, GDPR implications, and healthcare reimbursement policies affecting biochip commercialization.
      • Investment Opportunity Assessment : Evaluate market entry opportunities across high-growth European markets with detailed economic indicators, healthcare spending trends, and technology adoption rates by country.

      Frequently asked questions

      What is the current size of Europe's biochips market in 2025?

      Europe's biochips market is valued at $3,546 million in 2025, reflecting strong demand for diagnostic and therapeutic biochip solutions across the region.

      What is the projected market size for Europe's biochips market by 2030?

      Europe's biochips market is forecast to reach $5,450.9 million by 2030, representing significant expansion driven by precision medicine adoption and healthcare innovation.

      What is the CAGR for Europe's biochips market from 2025 to 2030?

      Europe's biochips market is expected to grow at a compound annual growth rate of 9.0% between 2025 and 2030.

      What factors are driving growth in Europe's biochips market?

      Europe's biochips market growth is driven by advanced healthcare infrastructure, regulatory support, precision medicine initiatives, genomic research investments, and strong pharmaceutical and diagnostics sectors.

      Which applications are leading Europe's biochips market expansion?

      Diagnostic biochips, therapeutic biochips, and point-of-care testing solutions are leading Europe's market expansion, supported by adoption in hospitals, research institutions, and diagnostic laboratories.

      RESEARCH METHODOLOGY

      This research study extensively utilized both primary and secondary sources. It involved analyzing various factors influencing the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and strategies employed by key players.

      Secondary Research

      This research study utilized a variety of comprehensive secondary sources, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the biochips market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments pertaining to both market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.

      Primary Research

      In the primary research process, we interviewed a range of sources from both the supply and demand sides to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the biochips market. Primary sources from the demand side include researchers in biotechnology and pharmaceutical companies, healthcare professionals from hospitals and diagnostic centers, academic & research institutes and contract research organizations.

      A breakdown of the primary respondents is provided below:

      Biochips Market

      Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.

      Note 2: Other designations include sales, marketing, and product managers.

      Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The total size of the biochips market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

      Biochips Market

      Data Triangulation

      After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

      Market Definition

      The biochips market refers to miniaturized analytical platforms integrating biological probes or microfluidic components that allow simultaneous or rapid analysis of DNA, RNA, proteins, metabolites, or tissues. They are fabricated as microarrays, microfluidic cartridges, or tissue arrays and used in diagnostics, genomics, proteomics, drug discovery, and pathology research. These biochips enable high-throughput screening, providing faster, more efficient testing methods, and are critical in applications such as personalized medicine, disease detection, and environmental monitoring. With advances in technology, biochips are becoming increasingly versatile, supporting the development of novel diagnostics and therapeutic solutions across multiple sectors.

      Stakeholders

      • Pharmaceutical Companies
      • Biotechnology Companies
      • Research Institutes
      • Academic Institutes
      • Contract Research Organizations
      • Research and Consulting Companies
      • Biochip Manufacturers and Distributors
      • DNA & Gene Chip Manufacturers and Distributors
      • Protein Microarray Manufacturers and Distributors
      • Lab-on-a-Chip Manufacturers and Distributors
      • Cell & Tissue Array Manufacturers and Distributors

      Report Objectives

      • To define, describe, segment, and forecast the biochips market by products & services, type, fabrication technology, end user, and region
      • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biochips market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the biochips market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
      • To profile the key players in the biochips market and comprehensively analyze their core competencies and market shares
      • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

       

      Get the Full Biochips Market Report

      Full forecast, segment splits, and company analysis for all Biochips Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status